Streetbeat News

ASND

Ascendis Pharma A/S

Industry

Biotechnology

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Open

127.40

Mkt cap

7.1B

Volume

382K

High

127.99

P/E Ratio

-13.18

52-wk high

161.00

Low

124.11

Div yield

N/A

52-wk low

86.55

Ascendis Pharma (NASDAQ:ASND) has significantly outperformed the market over the past decade, with an annualized return of 55.34%, turning a $100 investment into $8,187.29 today. The company's market capitalization stands at $8.28 billion.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:00 pm

JP Morgan analyst Jessica Fye maintains an Overweight rating on Ascendis Pharma (ASND) and raises the price target from $165 to $167.

Portfolio Pulse from Benzinga Newsdesk

April 02, 2024 | 2:47 pm

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Ascendis Pharma (ASND) and maintained a $173 price target. This reaffirms the firm's positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

April 01, 2024 | 12:35 pm

Wells Fargo analyst Derek Archila has maintained an Overweight rating on Ascendis Pharma (ASND) and increased the price target from $196 to $260.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:41 pm

Over the past 15 years, Ascendis Pharma (NASDAQ:ASND) has produced an average annual return of 29.06%, outperforming the market. A $100 investment in ASND 15 years ago would now be worth $4,550.30. Ascendis Pharma currently has a market capitalization of $8.72 billion.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 2:00 pm

Ethan Meyers of Westfield Capital Management, known for his successful investment picks for the Harbor Small Cap Growth Fund, sees potential in small-cap stocks despite the market's focus on large-cap growth stocks like Amazon, Apple, and Microsoft. He highlights a valuation gap, suggesting an opportunity for mean reversion that could benefit smaller companies. Meyers recommends five small-cap stocks: Ascendis Pharma, Comfort Systems, ITT Inc., Meritage Homes, and M/I Homes, each with unique growth prospects.

Portfolio Pulse from Bibhu Pattnaik

March 03, 2024 | 7:57 pm

Ascendis Pharma (NASDAQ:ASND) has significantly outperformed the market with an average annual return of 29.04% over the past 15 years, turning a $1000 investment into $45,392.55 today. The company's market capitalization stands at $8.96 billion.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 4:00 pm

Ascendis Pharma (NYSE:ASND) has seen a decrease in short interest, with 2.93 million shares sold short, representing 7.46% of its float. This is a decline of 6.4% from its last report, indicating a potential shift in market sentiment towards the stock. The current short interest suggests a more bullish outlook compared to its peers, with an average short interest of 4.40% in its peer group. Short interest is a key indicator of market sentiment, and a decrease suggests investors are becoming more optimistic about the stock's future performance.

Portfolio Pulse from Benzinga Insights

February 13, 2024 | 1:15 pm

Ascendis Pharma (NASDAQ:ASND) has significantly outperformed the market with an annualized return of 42.05% over the past 10 years, turning a $1000 investment into $69,635.47. The company now has a market capitalization of $7.88 billion.

Portfolio Pulse from Benzinga Insights

February 08, 2024 | 4:30 pm

Citigroup analyst David Lebowitz has maintained a Buy rating on Ascendis Pharma (ASND) and increased the price target from $146 to $182. This adjustment reflects a positive outlook on the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

February 08, 2024 | 4:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.